Medicinal folium artemisiae argyi composition for preventing and treating atherosclerosis combined skin suppurative bacterial infection

Abstract

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a medicinal composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial infection. Background Technology

[0002] Atherosclerosis is characterized by lipid deposition in the vascular endothelium, plaque formation, and luminal narrowing. Clinical manifestations include chest pain, palpitations, dizziness, and limb numbness; in severe cases, it can lead to ischemic events such as myocardial infarction and stroke. Its pathogenesis is closely related to abnormal lipid metabolism, chronic inflammatory response, endothelial dysfunction, and oxidative stress. Modern medical research shows that atherosclerosis is a chronic inflammatory disease, and its occurrence is closely related to lipid metabolism disorders, oxidative stress, inflammatory response, and endothelial dysfunction. Multiple inflammatory factors (such as IL-6, CRP, and TNF-α) participate in plaque formation and progression.

[0003] Purulent bacterial skin infections are mainly caused by Staphylococcus aureus, Streptococcus, etc., and manifest as local redness, swelling, heat, pain, pus formation, and skin lesions. The infection can release pro-inflammatory substances such as alpha toxins, exacerbating the systemic inflammatory response.

[0004] Current Western medicine treatments include: 1. Antibiotics: Penicillin and cephalosporins can control skin infections, but drug resistance exists; 2. Anti-inflammatory treatment: NSAIDs can relieve inflammation, but long-term use can lead to gastrointestinal damage and kidney dysfunction; 3. Lipid-lowering treatment: Statins can stabilize plaques, but may cause side effects such as myopathy; 4. Surgical treatment: Stent implantation can improve vascular stenosis, but it is invasive and carries the risk of restenosis. While Western medicine can control symptoms, it lacks synergistic treatment options for comorbidities, and long-term medication has significant side effects.

[0005] Current TCM treatment methods include: 1. Clearing heat and detoxifying: honeysuckle, forsythia, etc., can relieve skin infections; 2. Promoting blood circulation and removing blood stasis: salvia miltiorrhiza, safflower, etc., can improve arteriosclerosis; 3. External application of Chinese medicine: Ruyi Jinhuang San, etc., can promote skin healing. TCM treatment is holistic, but it lacks standardized protocols for arteriosclerosis complicated by skin infections, and its efficacy evaluation lacks evidence-based medicine. Summary of the Invention

[0006] The purpose of this invention is to provide a drug composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial infection.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows: A medicinal composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial skin infections, comprising a traditional Chinese medicine composition and mugwort floss, wherein the traditional Chinese medicine composition is made from the following raw materials in the indicated weight ratios: 4-23 parts Coptis chinensis, 4-21 parts Rehmannia glutinosa, 4-23 parts Polygala tenuifolia, and 5-27 parts Juncus effusus, and the weight ratio of the traditional Chinese medicine composition to the mugwort floss is 3-7.5:6-16.

[0008] To further realize the present invention, the traditional Chinese medicine composition in the above-mentioned medicated mugwort composition is preferably made from the following raw materials in the following weight ratio: 11 parts of Coptis chinensis, 11 parts of Rehmannia glutinosa, 10 parts of Polygala tenuifolia and 14 parts of Juncus effusus, and the weight ratio of the traditional Chinese medicine composition to mugwort floss is 5:11.

[0009] The advantages of this invention compared to the prior art are as follows: I. The rationale behind the formula and the properties and meridian tropism of the drugs: Traditional Chinese medicine theory holds that atherosclerosis falls under the category of "blood vessel disease," often caused by excessive heart fire and the accumulation of phlegm and blood stasis; skin infections are related to upward flaring of heart fire and the accumulation of damp-heat toxins. Both are related to dysfunction of the Hand Shaoyin Heart Meridian, where excessive heart fire can simultaneously lead to blood vessel obstruction and skin heat toxins.

[0010] Coptis chinensis is the principal herb in the formula, possessing the effects of clearing heat and drying dampness, purging fire and detoxifying. It is especially good at clearing heart fire and treating symptoms such as irritability, insomnia, and oral ulcers caused by excessive heart fire. Rehmannia glutinosa is the assistant herb, possessing the effects of clearing heat and cooling blood, nourishing yin and generating fluids, and moistening the intestines. It can assist Coptis chinensis in clearing heart fire while preventing Coptis chinensis from damaging yin due to its bitter and cold nature. Polygala tenuifolia is the adjuvant herb, possessing the effects of calming the mind and improving intelligence, resolving phlegm and opening the orifices, and dissipating carbuncles and swellings. It can regulate the mind and improve insomnia and dreaminess, and also has the effect of dissipating carbuncles and swellings. It has a certain curative effect on purulent skin infections. Juncus effusus is the adjuvant herb, possessing the effects of clearing heart fire and promoting urination. It can guide heart fire downward and promote the excretion of metabolic waste. Artemisia argyi is the adjuvant herb, possessing the effects of warming the meridians and dispelling cold, promoting blood circulation and unblocking collaterals, removing dampness and relieving itching, and killing parasites and stopping bleeding. It can warm and unblock the meridians, dispel cold and relieve pain, and also has broad-spectrum antibacterial effects.

[0011] The formulation of this invention embodies the traditional Chinese medicine principle of "combining cold and warm properties." Coptis chinensis, Rehmannia glutinosa, and Juncus effusus are cold in nature, possessing volatile properties that clear heat, cool the blood, purge fire, and detoxify. Polygala tenuifolia and Artemisia argyi are warm in nature, possessing volatile properties that warm and unblock the meridians, dispel cold, and relieve pain. The entire formula can both clear heart fire and treat heat syndromes, and warm and unblock the meridians, preventing coldness from damaging the spleen and stomach, thus achieving a balance of medicinal properties. The warm volatile components of Artemisia argyi can neutralize the cold volatile components of Coptis chinensis, Rehmannia glutinosa, and Juncus effusus, preventing the bitter and cold from harming the spleen and stomach. Simultaneously, its antibacterial effect can enhance the antibacterial effects of Coptis chinensis and Juncus effusus. The bitter and cold volatile components of Coptis chinensis can inhibit the excessively warm and drying volatile components of Rehmannia glutinosa and Juncus effusus, preventing heat and dryness from damaging yin. The warm volatile components of Polygala tenuifolia can assist Coptis chinensis in clearing heart fire, while its calming and intellect-enhancing effects can improve restlessness, reduce anxiety and stress, and indirectly improve arteriosclerosis and skin infections.

[0012] II. Mechanism of action of topical volatile agents in preventing and treating atherosclerosis: The medicated composition of the present invention targets the comorbidity of atherosclerosis and purulent bacterial skin infection because there is a mutually reinforcing pathological cycle between atherosclerosis and skin infection. Inflammatory factors released by skin infection (such as IL-6 and CRP) can activate the inflammatory response of vascular endothelium and promote the formation of atherosclerotic plaques. Moreover, atherosclerosis leads to microcirculatory disorders, reduces local skin immunity, and makes it easy for secondary bacterial infections to occur.

[0013] In this invention, the volatile components released by the combustion of Artemisia argyi in the medicinal composition, together with the volatile oils of Coptis chinensis and Juncus effusus, regulate lipid metabolism through skin penetration. Berberine and palmatine in Coptis chinensis penetrate deep into the skin through volatility, inhibiting TMA lysin (CutC / D) in intestinal flora, reducing TMA production, and thus lowering TMAO biosynthesis. Saponins in Polygala tenuifolia penetrate the skin in volatile form, exhibiting antiplatelet aggregation effects, improving blood rheology, and reducing atherosclerotic plaque formation. The phenanthrene volatile components (such as dehydrojuncusin) and flavonoids of Juncus effusus are absorbed through the skin, lowering triglyceride and cholesterol levels and improving lipid metabolism disorders.

[0014] The berberine in Coptis chinensis of this invention, through its volatility, penetrates the skin and possesses antioxidant activity, inhibiting lipid peroxidation and protecting vascular endothelial function. Polysaccharides and glycosides in Rehmannia glutinosa release volatile substances under heat, forming an antioxidant network. Flavonoids in Juncus effusus also have antioxidant effects, reducing vascular endothelial damage. Polyphenols (such as chlorogenic acid) in Artemisia argyi are released in volatile form, neutralizing free radicals in the body, delaying cell aging, and protecting the cardiovascular system. These volatile antioxidants work synergistically to form a powerful antioxidant network, protecting the vascular endothelium from oxidative stress damage.

[0015] The medicated composition of this invention inhibits inflammatory responses and alleviates the progression of atherosclerosis through multiple pathways. Berberine from Coptis chinensis, through its volatility, penetrates the skin and inhibits the release of nitric oxide, tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) from macrophages, thus reducing inflammatory responses. The saponin volatile components of Polygala tenuifolia have anti-inflammatory effects and can reduce atherosclerosis-related inflammatory responses. The phenanthrene volatile components of Juncus effusus and thujone from Artemisia argyi jointly inhibit the production of inflammatory factors. Flavonoids in Artemisia argyi, through volatile penetration, inhibit COX enzyme activity, reduce prostaglandin synthesis, and lower vascular inflammatory responses. These volatile components work synergistically to form a multi-layered anti-inflammatory mechanism, effectively inhibiting the inflammatory pathways of atherosclerosis.

[0016] The volatile components of Coptis chinensis and Polygala tenuifolia synergistically enhance vasodilatory capacity and reduce the formation of atherosclerotic plaques. The volatile oils in Artemisia argyi (such as α-terpinenol and thujone) and the phenanthrene volatile components in Juncus effusus work together to promote the recovery of vascular endothelial function and improve blood flow. The far-infrared radiation (40-60℃) generated by the burning of Artemisia argyi penetrates the skin 3-5 cm, directly acting on the blood vessel walls, dilating local capillaries, and accelerating blood circulation. The Artemisia argyi composition of this invention improves blood circulation through the mechanism of external application of volatile components, exhibiting a more direct and targeted approach compared to oral medications.

[0017] III. Mechanism of action of topical volatile agents for preventing and treating purulent bacterial skin infections The medicated composition of this invention exhibits significant volatile anti-inflammatory effects, reducing redness, swelling, heat, and pain at the site of skin infection. Berberine from Coptis chinensis, through its volatility, penetrates the skin, inhibiting the production of inflammatory factors (IL-6, TNF-α) and alleviating inflammatory responses. Polysaccharides and glycosides from Rehmannia glutinosa release volatile substances under heat, enhancing skin repair capabilities. Volatile saponins from Polygala tenuifolia reduce inflammatory responses at the site of skin infection by regulating immune responses. Volatile flavonoids from Juncus effusus, in conjunction with flavonoids from Artemisia argyi, inhibit COX enzyme activity, reduce prostaglandin synthesis, and decrease local inflammatory responses. Volatile polysaccharides from Artemisia argyi promote keratinocyte proliferation and repair damaged skin barriers; volatile components from Artemisia argyi reduce levels of inflammatory factors such as IL-4, achieving an itching relief rate of 72%.

[0018] The volatile oils of Coptis chinensis and Artemisia argyi work together to improve local microcirculation in the skin and accelerate the excretion of metabolic waste. The polysaccharide volatile components of Rehmannia glutinosa repair the skin barrier and prevent toxins from penetrating the body. The volatile components of Polygala tenuifolia reduce exudation by regulating capillary permeability, while promoting the excretion of inflammatory factors and toxins. The phenanthrene volatile components of Juncus effusus work together with the far-infrared radiation generated by the burning of Artemisia argyi to dilate blood vessels and promote blood circulation. Artemisia argyi can improve blood circulation and accelerate the recovery of infected areas.

[0019] IV. Synergistic Prevention and Treatment of Co-existing Comorbidities: External Volatile Compound Mechanisms There is an intrinsic link between the development of atherosclerosis and purulent bacterial skin infections, and chronic inflammation is the common pathological basis of these two diseases.

[0020] The medicated artemisia composition of the present invention inhibits inflammatory responses and alleviates the pathological basis of comorbidities through multiple pathways. Berberine from Coptis chinensis, through its volatility, penetrates the skin to inhibit the assembly and activation of the NLRP3 inflammasome, blocks the maturation and secretion of IL-1β and IL-18, and reduces the body's inflammatory response. The volatile components of Juncus effusus and Polygala tenuifolia also have anti-inflammatory effects and can synergistically reduce systemic and local inflammatory responses. The flavonoid volatile compounds in Artemisia argyi and the phenanthrene volatile components of Juncus effusus work together to inhibit COX enzyme activity, reduce prostaglandin synthesis, and lower the inflammatory response. The medicated artemisia composition of the present invention, through the mechanism of regulating inflammatory responses through topical volatile components, has a more direct and targeted characteristic.

[0021] The volatile polysaccharides in Rehmannia glutinosa, absorbed through the skin, can enhance the activity of immune cells and strengthen the body's resistance to pathogens. The volatile components of Polygala tenuifolia can regulate nervous system function, reduce stress responses, and improve immune function. The volatile oils and flavonoids in Artemisia argyi, absorbed through the skin, activate macrophage activity, increase lymphocyte transformation rate by 12%-18%, and enhance the body's immune defense capabilities. The phenanthrene and flavonoid volatile components of Juncus effusus work together to regulate immune responses and enhance the body's resistance to pathogens. These volatile immunomodulatory components work synergistically to form a multi-layered immune enhancement mechanism.

[0022] The medicated composition of this invention achieves comprehensive prevention and treatment of comorbidities through the synergistic action of multiple targets. The volatile components of Coptis chinensis reduce TMAO by inhibiting intestinal flora TMA lysin (CutC / D); the volatile components of Rehmannia glutinosa protect vascular endothelium through antioxidant effects; the volatile components of Polygala tenuifolia improve blood rheology by inhibiting platelet aggregation; the volatile components of Juncus effusus improve lipid metabolism by lowering triglycerides; and the volatile components of Artemisia argyi control skin infections through antibacterial and anti-inflammatory effects. These volatile components work synergistically at different targets, forming a multi-target therapeutic network to comprehensively intervene in the pathological process of comorbidities.

[0023] The pungent volatile components of Polygala tenuifolia (such as terpineol) can enhance the permeability of medicinal smoke and assist the transdermal absorption of the antibacterial component of Coptis chinensis (berberine). The pungent and warm volatile components of Artemisia argyi can promote the opening of skin pores and enhance drug permeability. The far-infrared radiation (40-60℃) generated by the burning of Artemisia argyi penetrates the skin 3-5 cm, promoting vasodilation and accelerating drug absorption. The Artemisia argyi composition of the present invention promotes drug absorption through the mechanism of external application of volatile components, and has the characteristics of higher efficiency and more targeted application. Attached Figure Description

[0024] Figure 1 This represents the intersection of active ingredients between different databases in the experimental examples of this invention; Figure 2 This represents the intersection of target points between different databases in the experimental examples of this invention. Figure 3 This is a Venn diagram showing the intersection of the target points of the herbal composition of Artemisia argyi in the experimental examples of this invention on the comorbidity of atherosclerosis combined with purulent bacterial skin infection. Figure 4 This is a drug-compound-target-disease network diagram from the experimental examples of this invention; Figure 5 This is a bar chart ranking the connectivity of compounds in the experimental examples of this invention. Figure 6 Sankey diagram of the drug source of the TOP compound in the experimental examples of this invention; Figure 7 This is a STRING interaction diagram from an experimental example of the present invention; Figure 8 This is a diagram of the PPI interaction network in the experimental examples of this invention; Figure 9 This is a bar chart ranking the connectivity of core target points in the experimental examples of this invention. Figure 10 This is a bar chart of GO enrichment analysis in the experimental examples of this invention; Figure 11 This is a pie chart of GO enrichment analysis in the experimental examples of this invention; Figure 12 This is a scatter plot of KEGG enrichment analysis in the experimental examples of this invention; Figure 13 This is a pie chart of KEGG enrichment analysis in the experimental examples of this invention; Figure 14 This is a Sankey diagram of the TOP pathway at the TOP target in the experimental examples of this invention. Figure 15 This is a compound-target-pathway-disease network diagram from the experimental examples of this invention; Figure 16 This is a heat map of the docking energy of the Top 10 active ingredients and Top 10 target sites in the experimental examples of this invention. Detailed Implementation

[0025] The present invention will be further described below with reference to the accompanying drawings and specific embodiments.

[0026] A medicinal composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial skin infections, comprising a traditional Chinese medicine composition and mugwort floss, wherein the traditional Chinese medicine composition is made from the following raw materials in the indicated weight ratios: 4-23 parts Coptis chinensis, 4-21 parts Rehmannia glutinosa, 4-23 parts Polygala tenuifolia, and 5-27 parts Juncus effusus, and the weight ratio of the traditional Chinese medicine composition to the mugwort floss is 3-7.5:6-16.

[0027] The traditional Chinese medicine composition in the above-mentioned medicated mugwort composition is preferably made from the following raw materials in the following weight ratio: 11 parts Coptis chinensis, 11 parts Rehmannia glutinosa, 10 parts Polygala tenuifolia and 14 parts Juncus effusus, with the weight ratio of the traditional Chinese medicine composition to mugwort floss being 5:11.

[0028] Example: Example 1: Coptis chinensis 120g, Rehmannia glutinosa 120g, Polygala tenuifolia 120g, Juncus effusus 150g, and Artemisia argyi 1020g.

[0029] Example 2: Coptis chinensis 220g, Rehmannia glutinosa 220g, Polygala tenuifolia 200g, Juncus effusus 280g, and Artemisia argyi 2024g.

[0030] Example 3: Coptis chinensis 345g, Rehmannia glutinosa 315g, Polygala tenuifolia 345g, Juncus effusus 405g, and Artemisia argyi 3008g.

[0031] Experimental examples, network pharmacology, and molecular docking: I. Research Methods: Using TCMSP / BATMAN / HERB / ETCM, chemical components of Coptis chinensis, Rehmannia glutinosa, Polygala tenuifolia, and Juncus effusus were collected. The active ingredients of the drug-artemisia composition of this invention were further screened using OB≥30% and DL≥0.18 as screening criteria. For targets obtained from databases, the gene names of drug targets were standardized and deduplicated using the Uniprot database. Finally, the active ingredients and targets of the drug were obtained. Disease-related targets were retrieved from the GeneCards / OpenTargets / CTD / DrugBank databases. Using "Atherosclerosis" as a keyword, disease-related targets were retrieved, and the gene names of disease targets were standardized and deduplicated. Similarly, disease-related targets were retrieved from the GeneCards / CTD / DrugBank databases. Using "SoftTissueInfections" as a keyword, disease-related targets were retrieved, and the gene names of disease targets were standardized and deduplicated. The intersection genes of atherosclerosis combined with purulent bacterial skin infection were used as the final genes for the disease. Finally, potential targets for atherosclerosis combined with purulent bacterial skin infection were obtained. Common targets were identified as targets related to the treatment of atherosclerosis complicated with purulent bacterial skin infection comorbidity by the medicated moxibustion composition of the present invention. The one-to-one correspondence between the active ingredients and targets of the medicated moxibustion composition of the present invention was imported into Cytoscape 3.9.1 software to construct a drug-compound-target-disease network diagram. A PPI network diagram was constructed using the STRING database, and the intersection targets related to the action of the medicated moxibustion composition of the present invention on atherosclerosis complicated with purulent bacterial skin infection comorbidity were imported into the STRING database to screen core targets. The relevant targets of the medicated moxibustion composition of the present invention and atherosclerosis complicated with purulent bacterial skin infection comorbidity were subjected to GO functional enrichment analysis and KEGG pathway enrichment analysis using the RclusterProfiler 4.6.2 package, respectively. Core TOP pathways and their key targets and active ingredients were selected to construct a "drug-compound-target-pathway-disease" network.

[0032] The 3D structures of the main active compounds in the drug composition of this invention were downloaded from the PubChem database, and the 3D structures of the core target proteins were downloaded from the Protein Data Bank database. Autodock Vina was used to perform the docking of the components and targets.

[0033] II. Results and Analysis: 1. Collection of active ingredients and target prediction of the drug composition of the present invention By searching drug databases, the components of the medicinal composition of this invention were retrieved, and active ingredients meeting the requirements of OB≥30% and DL≥0.18 were screened. Six active ingredients from Polygala tenuifolia, 21 from Juncus effusus, 17 from Coptis chinensis, and one from Rehmannia glutinosa were obtained. Duplicate common ingredients were removed, resulting in a total of 43 active ingredients. (See...) Figure 1 Potential drug targets for active pharmaceutical ingredients were identified through a database. After removing duplicate targets, a total of 689 drug targets were obtained. (See...) Figure 2 .

[0034] 2. Collection of relevant targets for comorbidities of atherosclerosis and purulent bacterial skin infection, and screening of therapeutic targets for the drug composition of the present invention. The results of the “Atherosclerosis” disease search were filtered according to thresholds using Gene Cards Score>=5 / Open Targets Score>=0.1 / CTD Score>=100 / Drug Bank database. Similarly, the results of the “Soft Tissue Infections” disease search were filtered according to thresholds using Gene Cards Score>=20 / CTD Score>=5 / Drug Bank database. Gene names of standardized disease targets were summarized, duplicates were removed, and the intersection was taken to obtain 254 disease targets. These targets were then mapped to the effective ingredient targets of the medicated composition of this invention. After mapping, 121 common targets were identified as potential targets for the medicated composition of this invention to act on atherosclerosis complicated by purulent bacterial skin infections. (See [link to relevant documentation]). Figure 3 .

[0035] 3. Construction and analysis of drug-compound-target-disease network See the drug-compound-target-disease network. Figure 4 The network graph has 167 nodes and 622 edges, with edges representing the targeting relationships between compounds and targets. 41 active ingredients act on 121 targets (some compounds whose targets were not in the intersection were removed). The network topology was analyzed using the Network Analyzer plugin. In the network graph, the size of a node represents its degree value; a higher degree value indicates a stronger pivotal role in the network. The degree values ​​of the top 20 principal components are ranked as follows: Figure 5 Based on this analysis, the main active ingredients found include quercetin, Berberine, luteolin beta-carotene, eckol, beta-sitosterol, and sitosterol. Figure 6 Different shapes represent drugs, compounds, and targets, and the shades of color represent the degree weights in the network.

[0036] 4. PPI Network Diagram Analysis 121 intersecting drug targets related to disease treatment were imported into the STRING database to obtain PPI relationships, and then imported into Cytoscape software for analysis. Figure 7 The network graph has 118 nodes and 1560 edges, where edges represent the relationships between target points (isolated target points with no intersection are removed). The Network Analyzer plugin is used to analyze the network topology, calculate degree values, and set the color intensity and node size to reflect the degree values. The top 30 core nodes are selected based on their degree values ​​(CC / BC / degree), and the network graph is then drawn. See [link to diagram]. Figure 8 The core targets are IL6, TNF, STAT3, AKT1, IL1B, TP53, and EGFR, which are key targets for the treatment of atherosclerosis complicated by purulent bacterial skin infections in the drug composition of this invention. (See below) Figure 9 .

[0037] 5. GO functional enrichment analysis and KEGG pathway analysis Based on R clusterProfiler, GO enrichment analysis was performed on 121 intersection targets related to drug treatment diseases. The top 15 items of biological process (BP), molecular function (MF), and cellular component (CC) with P < 0.05 were selected to create maps, as shown below. Figure 10-11 As shown. Figure 10 The vertical axis represents each entry of GO, and the horizontal axis represents the number of target sites enriched with that entry. Figure 11Medium-terminal cytokine (BP) mainly involves responses to peptide-mediated positive regulation of cytokine production, glandular development, cellular responses to chemical stress, responses to lipopolysaccharides, cellular responses to biological stimuli, responses to bacterial molecules, responses to extracellular stimuli, regulation of apoptosis signaling pathways, epithelial cell proliferation, responses to oxidative stress, and responses to peptide hormones. Medium-terminal cytokine (MF) mainly includes cytokine activity, receptor ligand activity, signal receptor activator activity, D-binding transcription factor binding, cytokine receptor binding, R polymerase II-specific D-binding transcription, ubiquitin-like protein ligase binding, ubiquitin-protein ligase binding, growth factor activity, protease binding, and heme binding. Medium-terminal cytokine (CC) mainly involves indented membrane rafts, membrane microdomains, transcriptional regulatory complexes, plasma membrane rafts, R polymerase II transcriptional regulators, vesicle cavities, endoplasmic reticulum cavities, protease inhibitory complexes, secretory granule cavities, cytoplasmic vesicle cavities, peptidase inhibitory complexes, and transcriptional inhibitory complexes. KEGG pathway enrichment analysis was performed on the target, resulting in 169 signal pathways. This invention selected the top 30 pathways with p < 0.05 from the downloaded results and visualized them for analysis. Figure 12-13 As shown. Enrichment results indicate that the AGE-RAGE signaling pathway is mainly involved in diabetes, lipids and atherosclerosis, prostate cancer, Kaposi's sarcoma-associated herpesvirus infection, IL-17 signaling pathway, bladder cancer, hepatitis B, human cytomegalovirus infection, proteoglycans in cancer, fluid shear stress and atherosclerosis, endocrine resistance, and the C-type lectin receptor signaling pathway. These pathways communicate with each other and play important roles in the occurrence and development of diseases. In addition, this invention also plotted a Sankey diagram of TOP pathways related to TOP targets, see [link to diagram]. Figure 14 .

[0038] 6. Construction and analysis of drug-compound-target-pathway-disease network This invention selects core TOP pathways and their key targets and active ingredients to construct a "compound-target-pathway-disease network." For example... Figure 15 As shown, the network consists of 197 nodes and 1297 edges (41 components, 121 targets, and 30 signaling pathways, drugs, and diseases). Different node shapes represent different active ingredients, key targets, and regulatory pathways in the medicated composition of this invention, and the color intensity represents the degree weight in the network. Each active ingredient corresponds to multiple targets, and each target connects to multiple components, reflecting the multi-component, multi-target mechanism of action of the medicated composition of this invention in preventing and treating comorbidities of atherosclerosis and purulent bacterial skin infections.

[0039] 7. Molecular docking Based on the ranking of active ingredient scores in the active ingredient-target network diagram and literature review, this invention performs molecular docking between the active ingredients MOL000006, MOL000098, MOL000358, MOL000359, MOL001454, MOL002773, MOL006149, MOL007899, MOL007907, and MOL010616 in the drug-artemisia composition of this invention and the top 10 core targets in the PPI network: AKT1, BCL2, EGFR, IL1B, IL6, JUN, NFKB1, STAT3, TNF, and TP53. The docking results are shown in […]. Figure 16 .

[0040] Clinical trial example: Clinical Trial Case 1: Hypertension Caused by Atherosclerosis Hypertension caused by atherosclerosis often manifests as dizziness and headache. Traditional Chinese medicine classifies hypertension into categories such as "dizziness" and "headache" based on its clinical symptoms.

[0041] 1. Materials and Methods 1.1 General Information Fifty patients with hypertension and dizziness who visited the outpatient clinics of the Traditional Chinese Medicine Department of Shehong Maternal and Child Health Hospital and Shapingba Tuwan Community Health Service Center in August 2024 were selected as the study subjects. There were 14 males and 36 females, aged 57-83 years, with a mean age of (69.760±5.861) years.

[0042] 1.2 Inclusion and Exclusion Criteria Inclusion criteria: (1) meeting the diagnostic criteria for hypertension and having clinical symptoms of dizziness; (2) patients voluntarily participating in this study and signing an informed consent form.

[0043] Exclusion criteria: (1) history of drug allergy; (2) patients with malignant tumors, dysfunction of vital organs, hematological diseases, abnormal immune function, or mental illness; (3) patients with poor treatment compliance who have difficulty cooperating with moxibustion on time.

[0044] 1.3 Grouping and Treatment Methods Fifty patients with hypertension and dizziness were randomly divided into a control group (n=25) and an experimental group (n=25). The control group was aged 57-80 years, with a mean age of (70.280±5.997) years. The experimental group was aged 60-83 years, with a mean age of (69.240±5.797) years. There were no statistically significant differences in patient data between the two groups. P >0.05), which is comparable, see Table 1.

[0045] The control group received oral antihypertensive medication combined with strong anti-vertigo tablets and regular moxibustion. The experimental group received oral antihypertensive medication combined with strong anti-vertigo tablets and moxibustion with the medicated moxa prepared from the composition in Example 2. Moxibustion was performed three times a week for 20 minutes each time, for a total of four weeks. Specific acupoints for moxibustion were: Shenmen, Dadun, and Taibai, bilaterally.

[0046] 1.4 Efficacy Evaluation Criteria The vertigo disability rating scale was used to assess the severity of vertigo on patients' physical, emotional, and functional aspects of life before and after treatment. The scale consists of 25 items and can evaluate the negative impact and severity of vertigo on patients' physical, emotional, and functional aspects of life.

[0047] 1.5 Statistical Analysis Data were analyzed using SPSS 27.0 software. Quantitative data were analyzed using... Represented in the form of, using Test whether the differences between the data are statistically significant.

[0048] 2 Results 2.1 Comparison of scores on the two groups of vertigo disability assessment scales Compared with before treatment, the scores of the Vertigo Disability Rating Scale in both groups decreased significantly after treatment. P <0.01 indicates that the dizziness symptoms of both groups of patients were significantly improved after treatment; compared with the control group, the experimental group had a lower score after treatment ( P <0.05), indicating that the medicated moxibustion prepared with the composition in Example 2 is more effective than ordinary moxibustion. See Table 2.

[0049] Clinical Trial Case 2: Skin Bacterial Infection Bacterial skin infections are usually caused by Staphylococcus aureus or Streptococcus pyogenes, and can lead to redness, swelling, pain, suppuration, and even ulceration at the site of infection. In Traditional Chinese Medicine, these infections fall under the categories of "sores" and "eczema."

[0050] 1. Materials and Methods 1.1 General Information Fifty patients with bacterial skin infections who visited the outpatient clinics of the Traditional Chinese Medicine Department of Shehong Maternal and Child Health Hospital and Shapingba Tuwan Community Health Service Center from August to October 2024 were selected as the study subjects. There were 21 males and 29 females, aged 24-80 years, with a mean age of (59.480±14.273) years.

[0051] 1.2 Inclusion and Exclusion Criteria Inclusion criteria: (1) Clinical diagnosis of skin bacterial infection; (2) Patients voluntarily participate in this study and sign informed consent form. Exclusion criteria: (1) History of drug allergy; (2) Patients with malignant tumors, dysfunction of vital organs, hematological diseases, abnormal immune function, or mental illness; (3) Patients with poor treatment compliance and difficulty in cooperating with moxibustion on time.

[0052] 1.3 Grouping and Treatment Methods Fifty patients with bacterial skin infections were randomly divided into a control group (n=25) and an experimental group (n=25). The control group consisted of 11 males and 14 females, aged 24-77 years, with a mean age of (58.480±14.973) years. The experimental group consisted of 10 males and 15 females, aged 26-80 years, with a mean age of (60.480±13.772) years. There were no statistically significant differences in age between the two groups. P >0.05), which is comparable, see Table 3.

[0053] Patients in the control group received topical mupirocin ointment combined with regular moxibustion, while patients in the experimental group received topical mupirocin ointment combined with moxibustion using the medicated moxa prepared from the composition in Example 1. Moxibustion was performed three times a week for 20 minutes each time, for a total of two weeks. Specific acupoints for moxibustion were: Shenmen, Dadun, and Taibai, bilaterally.

[0054] 1.4 Efficacy Evaluation Criteria Clinical symptom scores of skin bacterial infection were recorded before and after treatment. See Table 4 below.

[0055] 1.5 Statistical Analysis Data were analyzed using SPSS 27.0 software. Quantitative data were analyzed using... Represented in the form of, using Test whether the differences between the data are statistically significant.

[0056] 2 Results Comparison of clinical symptom scores of bacterial skin infections between the two groups: Compared with before treatment, the clinical symptom scores of bacterial skin infections in both groups decreased significantly after treatment. P <0.01 indicates that the skin infection symptoms of both groups of patients were significantly improved after treatment; compared with the control group, the experimental group had a lower score after treatment ( P <0.05), indicating that the medicated moxibustion prepared by the composition in Example 1 is more effective than ordinary moxibustion. See Table 5.

[0057] .

Claims

1. A drug composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial infection, characterized in that, The medicinal composition comprises a traditional Chinese medicine composition and mugwort floss. The traditional Chinese medicine composition is made from the following raw materials in the following weight ratio: 4-23 parts of Coptis chinensis, 4-21 parts of Rehmannia glutinosa, 4-23 parts of Polygala tenuifolia, and 5-27 parts of Juncus effusus. The weight ratio of the traditional Chinese medicine composition to the mugwort floss is 3-7.5:6-16.

2. The medicated composition for preventing and treating comorbidities of atherosclerosis and purulent bacterial infection as described in claim 1, characterized in that, The medicinal composition comprises a traditional Chinese medicine composition and mugwort floss. The traditional Chinese medicine composition is made from the following raw materials in the following weight ratio: 11 parts Coptis chinensis, 11 parts Rehmannia glutinosa, 10 parts Polygala tenuifolia and 14 parts Juncus effusus. The weight ratio of the traditional Chinese medicine composition to the mugwort floss is 5:11.

Images